data-ke-size="size16">LianBio, a biotechnology company committed to bringing innovative medicines to patients in China and other major Asian markets, has recently announced a clinical supply agreement with AstraZeneca in China. The purpose of this agreement is to assess the safety and effectiveness of BBP-398, an investigational SHP2 inhibitor, when used in combination with AstraZeneca's osimertinib, an epidermal growth factor receptor (EGFR) inhibitor. This evaluation will be conducted through a Phase 1 clinical study that aims to treat patients with non-small cell lung cancer (NSCLC) who carry EGFR mutations.
Yizhe Wang, Ph.D., the Chief Executive Officer of LianBio, stated that a significant number of NSCLC patients in China have EGFR mutations. While EGFR inhibitors are currently considered standard care for these patients, many eventually develop resistance to these treatments. Wang believes that BBP-398, as a unique SHP2 inhibitor, has the potential to restore sensitivity to EGFR inhibitors when used in combination therapy.